Lung cancer is the leading cause of cancer death in the United States, and approximately 85% of these patients have non–small cell lung cancer (NSCLC) subtypes. Approximately 60% of patients with NSCLC have metastatic disease at the time of diagnosis.
1,2 Historically, patients with metastatic disease received a platinum-based doublet as first-line therapy. Epidermal growth factor receptor (
EGFR)–activating mutations, defined as an exon 19 deletion or exon 21 L858R mutation, are associated with benefit from EGFR tyrosine kinase inhibitors (TKIs).
3,4 In the United States and Europe, approximately 10% to 15% of NSCLC with adenocarcinoma histologic type harbor an activating
EGFR mutation.
5-7 Phase 3 clinical trials compared erlotinib with platinum-based doublet in patients with advanced NSCLC with
EGFR exon 19 or exon 21 L858R mutation and found that patients in the erlotinib arms experienced a statistically significant higher objective response rate (ORR) and longer progression-free survival (PFS).
8,9 These phase 3 trials established erlotinib as a standard first-line therapy for patients with metastatic NSCLC with
EGFR exon 19 and exon 21 L858R mutations. Additional phase 3 clinical trials comparing EGFR TKIs with chemotherapy demonstrated an improvement in ORR and PFS with the EGFR TKIs, and the improvement in PFS was considered clinically meaningful and sufficient for regulatory approval worldwide.
8-12